Cradle Secures $73M to Advance AI-Driven Protein Engineering Platform

Cradle Secures $73M in Series B Funding

Cradle Bio B.V., an Amsterdam-based startup, has successfully raised $73 million in a Series B funding round led by IVP, with participation from Index Ventures and Kindred Capital 1

1

2

2

. This latest investment brings Cradle's total funding to over $100 million, highlighting the growing interest in AI-driven biotechnology solutions 3

3

.

Revolutionary AI Platform for Protein Engineering

Cradle's platform leverages generative artificial intelligence models to accelerate the discovery and development of proteins. The technology works similarly to OpenAI's ChatGPT, utilizing a generative protein language model trained on billions of known protein sequences 1

1

. This innovative approach allows scientists to design and engineer proteins more efficiently, addressing challenges across various industries including therapeutics, diagnostics, food, chemicals, and agriculture 2

2

.

Transforming Traditional Protein Engineering Methods

Traditional protein engineering methods are often slow, expensive, and rely heavily on trial and error. These processes can require 10 to 20 experimental rounds, each taking up to 8-12 weeks 1

1

. Cradle's AI-driven platform aims to revolutionize this landscape by:

1. Reducing experimental rounds by up to 90%
2. Cutting costs by hundreds of thousands of dollars in early research
3. Significantly boosting project success rates 1

   1

   2

   2

Wide-Ranging Applications and Industry Impact

The potential applications of Cradle's technology are vast and impactful:

• Developing new vaccines and sustainable chemicals
• Creating novel diagnostics
• Advancing agricultural crop protection
• Engineering enzymes, antibodies, and bio-based materials 1

  1

  2

  2

Industry leaders such as Novo Nordisk and Johnson & Johnson are already leveraging Cradle's platform to accelerate innovation 2

2

.

Expanding Capabilities and Team

With the new funding, Cradle plans to:

1. Expand its laboratory to generate new datasets for training its generative protein models
2. Enhance its AI capabilities by growing the engineering team
3. Scale its operations to meet growing demand in research-intensive industries 1

   1

   3

   3

Market Potential and Industry Trends

The investment in Cradle aligns with broader trends in AI-driven pharmaceutical and protein research. The global AI drug discovery market is estimated to reach $11.9 billion by 2033, up from $2.07 billion in 2024 1

1

. This growth reflects the increasing adoption of AI technologies in biotech and pharmaceutical industries.

Cradle's Unique Approach and Business Model

Unlike some competitors who focus on close partnerships for drug co-development, Cradle operates on a Software-as-a-Service (SaaS) model. This approach allows customers to retain all intellectual property rights to engineered proteins and maintain strict control over their data 1

1

3

3

. CEO Stef van Grieken emphasizes the company's goal to democratize access to AI in drug discovery and development, aiming to put their software "into the hands of a million scientists" 2

2

3

3

.